AGP Executive Report

EU Travel Rules: The EU’s Entry/Exit System (EES) is now fully operational, replacing passport stamps with a digital record of entries/exits plus facial images and fingerprints for eligible non-EU short-stay visitors. US Health & Safety Context: CENTCOM says recent reports about conditions aboard the USS Abraham Lincoln are false, including claims of deaths in a brawl and a spike in suicidal ideation. Weight-Loss Drug Deal: Gan & Lee’s weight loss drug rights in Europe were sold to Menarini for up to EUR726 million, with Menarini gaining commercialization rights across EU plus Liechtenstein and several other European markets. Climate & Health: July 2026 tied with July 2024 as the hottest month on record, raising the stakes for heat-related health risks. Travel Documents: A reminder for travellers: passports generally need at least three months’ validity beyond planned departure (and must be issued within the last 10 years) for trips to EU countries and several European states including Liechtenstein. Public Trust: Forbes-branded “Liechtenstein” and “LA” sites are reported as fake, with AI-generated content and paid-for placement schemes flagged.

E.U. Travel Rules: The EU Entry/Exit System (EES) is now fully operational, replacing passport stamps with a digital record of non-EU short stays (up to 90 days in 180) plus facial images and fingerprints—so trips through Schengen borders may look different from before. U.S. Drone Tariffs: The Trump administration is using Section 232 to impose drone import tariffs up to 100% for heavier, more capable systems, with lower rates for some EU/Swiss-origin equipment—raising costs that could ripple into defense-linked tech supply chains. Weight Loss Drug Deal: Gan & Lee’s obesity/overweight GLP-1 injection rights in Europe (including Liechtenstein) have been sold to Menarini for up to about EUR726 million, with down payment and milestone payments plus royalties. Climate & Health Context: July 2026 tied with July 2024 as the hottest July on record, underscoring rising heat risks for public health. Local Safety & Trust: CENTCOM says recent reports about deaths or mental health crises aboard USS Abraham Lincoln are false, pointing to crew reenlistment rates and a recovered sailor. Health Tech Watch: The SEC is set to vote on “Regulation Crypto Assets,” aiming to create a tailored offering path for certain crypto investment contracts. Public Info Integrity: Forbes-branded fake sites, including “Forbes Liechtenstein,” are being flagged as AI-generated and paid-for, with the publisher taking action.

EU Travel Rules: The EU’s Entry/Exit System (EES) is now fully operational, replacing passport stamps with a digital record of entries and exits plus facial images and fingerprints for eligible non-EU short-stay visitors (up to 90 days in 180). Public Health & Climate: July 2026 has tied with July 2024 as the hottest July on record, with NOAA and NASA reporting record heat—an ongoing reminder for heat-risk planning and health protection. Medicine & Weight Loss: Gan & Lee’s weight-loss drug Bofenglutide is moving into a wider European rollout as Menarini buys commercialization rights for overweight/obesity across EU and several partner countries, with down payments and milestone payments involved. Travel Safety (Passports): A UK travel advisory highlights strict passport validity rules for trips to EU countries and several European states, with at least three months left after departure and passports issued within the last 10 years. Local Relevance: Liechtenstein is explicitly named in the EES rollout context and in the Bofenglutide licensing region.

EU Travel Rules: The EU’s Entry/Exit System (EES) is now fully operational, replacing passport stamps with a digital record of non-EU short stays (up to 90 days in 180) plus facial images and fingerprints at entry and exit. Liechtenstein in the Tariff Mix: A US Section 232 drone tariff order sets a 15% rate for equipment from the EU band that includes Liechtenstein, but only if all hardware, software and technology substantially originates in qualifying countries or the US. Health & Weight-Loss Drug Deal: Gan & Lee’s obesity/overweight GLP-1 injection Bofenglutide rights for Liechtenstein and other European markets have been licensed to Menarini in a deal worth up to EUR726 million, with down payment and milestone payments plus royalties. Climate Watch: July 2026 tied with July 2024 as the hottest July on record, with NOAA noting the global average temperature for January–July 2026 among the highest ever. Local Wellness Angle: A singer’s urgent passport-eligibility plea highlights strict EU travel rules—passports need enough remaining validity and must be issued within a set timeframe.

EU Travel & Borders: The EU’s Entry/Exit System (EES) is now fully operational, replacing passport stamps with a digital record of non-EU short-stay entries and exits (up to 90 days in 180), including facial images and fingerprints—so travelers to Schengen may notice a different border process. Health & Weight-Loss Drugs: Gan & Lee’s weight-loss drug Bofenglutide (a GLP-1 injection) has been licensed for commercialization across much of Europe (including Liechtenstein) to Menarini in a deal worth up to EUR726 million, with down payment and milestone payments plus royalties. Climate & Public Health: July 2026 tied with July 2024 as the hottest July on record, raising the stakes for heat-related health planning across Europe. Local Relevance: Pope Leo XIV appointed new members to the Vatican’s Council for the Economy, including Liechtenstein’s princess Gisela Bergmann, highlighting continued cross-border leadership in health-adjacent policy and governance. Travel Rules: A reminder for EU travel after Brexit: passports generally need at least three months’ validity beyond departure (and be issued within 10 years) for many destinations including Liechtenstein.

EU Border Update: The EU’s Entry/Exit System (EES) is now fully operational, replacing passport stamps with a digital record of non-EU short stays (up to 90 days in 180) plus facial images and fingerprints at entry/exit points. Public Health & Climate: July 2026 has tied with July 2024 as the hottest month on record, raising the heat-health stakes for Europe, including Liechtenstein. Medicines & Weight Loss: Gan & Lee’s weight-loss drug rights in Europe were sold to Menarini for up to about USD839 million, with Bofenglutide (a GLP-1 injection) targeted for overweight/obesity use across multiple European markets including Liechtenstein. Reproductive Health Politics: Liechtenstein’s regent, Prince Alois, says he will block any move to legalise abortion, keeping it restricted to limited medical grounds. Travel Rules Reminder: A reminder that passports need enough remaining validity for travel to EU countries and nearby states, including Liechtenstein, to avoid last-minute trip problems.

Alpine Endurance & Safety: New Zealand ultrarunner Sophie Woods says she feared for her life during a thunderstorm while smashing the Via Alpina 2,000km record, after scaling a Swiss peak as lightning struck nearby rocks. Public Health & Weight Loss Drugs: Gan & Lee Pharmaceuticals’ weight-loss drug Bofenglutide is set for a major Europe push after Menarini bought commercialization rights across EU states plus Switzerland, Norway, Iceland, Liechtenstein and more, with down payments and milestone payments totaling hundreds of millions. Reproductive Health Policy: Liechtenstein’s regent, Hereditary Prince Alois, vowed to block any move to legalise abortion, citing his veto power and the country’s current limited exceptions. Climate & Heat Risks: NOAA reports July 2026 tied with July 2024 as the hottest July on record, underscoring rising heat exposure concerns for outdoor activity and health. Digital Health/Access (EU travel): A travel-rule reminder highlights that passports need at least three months’ validity for EU travel (including Liechtenstein-linked routes), a practical issue for health-related travel planning.

Crypto Regulation Watch: The US SEC has scheduled an Aug 14 open meeting to propose “Regulation Crypto Assets,” aiming to let qualifying crypto projects raise up to $75M without full SEC registration. Weight-Loss Drug Deal: China’s Gan & Lee surged after selling European rights to its two-weekly GLP-1 weight-loss drug Bofenglutide to Menarini for up to EUR726M, covering EU states plus Switzerland, Norway, Iceland, Liechtenstein and more. Climate & Health: July 2026 tied with July 2024 as the hottest July on record, with NOAA and NASA reporting record heat—another reminder of rising heat risks for public health. Local Health Politics: Liechtenstein’s hereditary prince says he will block any move to legalise abortion, keeping it restricted to limited cases. Clean Water & Wellness: A Schaan-based Liechtenstein firm, Dropvital, is building water-treatment services with a focus on traceable, organic natural-product quality. Digital Health/Access: A UK family-visa guidance update highlights settlement options after a partner’s death, including eligibility for nationals from Switzerland, Norway, Iceland and Liechtenstein.

Crypto Regulation Watch: The US SEC has scheduled an Aug 14 open meeting to propose “Regulation Crypto Assets,” aiming to let qualifying crypto projects raise up to $75M under a lighter, tailored offering regime instead of full SEC registration. Weight-Loss Drug Deal: China’s Gan & Lee surged after selling European rights to its GLP-1 weight-loss drug Bofenglutide to Menarini for up to about USD839M, covering obesity and overweight indications across Europe including Liechtenstein. Climate & Health Link: NOAA reports July 2026 tied with July 2024 as the hottest July on record, with NASA rating it the hottest ever—another reminder that heat extremes can strain health systems. Liechtenstein Reproductive Politics: Hereditary Prince Alois says he will block any move to legalise abortion in Liechtenstein, keeping it restricted to sexual assault or to protect the mother’s health. Public Trust Online: Forbes warns about fake, AI-generated “Forbes” sites and a PR agency offering guaranteed placement for fees, raising concerns about misinformation and mental load. Travel Rule Reminder: UK guidance highlights passport rules after Brexit for travel to EU countries and Switzerland, Norway, Iceland—and Liechtenstein—requiring at least three months’ validity.

Health Tech & Safety: A Liechtenstein-linked PR scam is making the rounds: fake “Forbes” sites (including “Forbes Liechtenstein”) are packed with paid promotional posts, with AI-written pieces and hard-to-trace bylines; Forbes says the sites are fake and is taking action. Global Health & Drugs: Gan & Lee’s weight-loss drug deal is a big one for Europe: Menarini has bought rights to commercialize Bofenglutide for overweight/obesity across EU states plus Switzerland, Norway, Iceland, Liechtenstein and more, with upfront and milestone payments and royalties. Climate & Public Health: July 2026 is tied with July 2024 as the hottest month on record, raising the stakes for heat-related health risks. Local Health Policy: Liechtenstein’s regent, Prince Alois, says he will block any move to legalise abortion beyond current limits, noting many women still travel abroad for care. Wellness Lifestyle: If you’re planning a healthier routine while traveling, Bulgaria’s new digital nomad visa is being pitched as an affordable base for hiking and longer stays.

Environment & Health: A UK “reset” with Europe is being urged to start with environmental cooperation, including rejoining the European Environment Agency and its monitoring network—because pollution and climate risks don’t respect borders. Climate Watch: July 2026 has tied with July 2024 as the hottest July on record, with NOAA reporting the tie and NASA and Copernicus ranking it among the top extremes—another reminder for heat and air-quality planning. Obesity Drug Deal (EU/CH/LI): Gan & Lee’s weight-loss drug rights in Europe (including Switzerland and Liechtenstein) were sold to Menarini for up to about USD839m, with a two-weekly GLP-1 injection aimed at overweight and obesity. Liechtenstein in Focus (Finance): Pope Leo XIV appointed Liechtenstein’s Princess Gisela Bergmann to the Vatican Council for the Economy, adding a local figure to major financial oversight. Local Health Risk (Data Breach): Brown Health Medical Group-MA says 311,000 people were hit by a December 2025 breach involving personal and medical-related records. Reproductive Health Policy: Liechtenstein’s regent Prince Alois says he will block moves to legalise abortion beyond current limits. Travel Rules That Affect Wellness: UK guidance warns travellers about passport validity and strict rules on bringing meat and dairy back from EU countries (including Liechtenstein), to avoid fines.

Digital Health & Travel: Bulgaria’s new digital nomad visa is drawing attention from health-minded travelers who want longer stays with easier work-from-anywhere logistics, with the country pitching affordable living and outdoor options like hiking and skiing. Climate & Wellbeing: July 2026 has tied with July 2024 as the hottest July on record, a reminder that heat risk is a real public-health issue for daily routines, sleep, and hydration. Healthcare Innovation & Access: Gan & Lee’s weight-loss drug Bofenglutide is moving into Europe via Menarini, covering overweight/obesity use across EU states including Switzerland and Liechtenstein—potentially shaping future GLP-1 access and competition. Local Health Policy: Liechtenstein’s regent Prince Alois says he will block efforts to legalise abortion, keeping the current limits (only in cases like sexual assault or to protect the mother’s health). Data Privacy: Brown Health Medical Group-MA says a breach affected 311,000 people, with personal and medical-related records potentially exposed—another nudge for stronger safeguards and patient monitoring.

Weight-loss drug deal: Gan & Lee Pharmaceuticals’ shares jumped after it sold European rights to its biweekly GLP-1 injection Bofenglutide to Menarini for up to about USD839m, with Menarini covering overweight/obesity across EU states plus the UK, Switzerland, Norway, Iceland, Liechtenstein and parts of the Balkans. Local health policy: Liechtenstein’s regent, Prince Alois, says he will block any move to legalise abortion, citing his veto power as support grows for first-trimester access. Healthcare data breach: Brown Health Medical Group-MA is warning 311,000 people after a December 2025 file-server breach exposed personal, medical/disability, and financial details. Travel health & admin: A singer’s urgent passport plea highlights a common rule for travel to EU countries and Switzerland/Norway/Iceland/Liechtenstein: passports must have at least three months left and be issued within the last 10 years. Wellness-adjacent business: Dropvital, based in Schaan, Liechtenstein, positions its water-treatment and organic medicinal mushroom approach around traceability and quality.

Abortion Law in Focus: Liechtenstein’s hereditary Prince Alois says he will veto any move to legalise abortion, keeping the procedure illegal except in limited cases like sexual assault or to protect the mother’s health; reports note around 40 women travel to Austria or Switzerland each year for abortions. Health Data Security: Brown Health Medical Group-MA is warning 311,000 people after a December 2025 data breach exposed personal, medical, and financial details, including IDs and disability-related records. Cancer Treatment Access: IMPACT Therapeutics and Pharmanovia signed an exclusive licensing deal to expand senaparib for ovarian cancer maintenance therapy across 66 countries, including Liechtenstein and the wider EEA. Travel Rules That Affect Health Access: UK guidance highlights passport validity rules for travel to EU countries and Switzerland, Norway, Iceland, Liechtenstein and others—an issue that can derail urgent trips. Food Import Safety: UK customs rules restrict bringing meat and dairy (including cheese and milk products) into the UK from Liechtenstein and other listed countries, with potential fines for violations.

Abortion Policy in Liechtenstein: Hereditary Prince Alois, regent of Liechtenstein, says he will veto any move to legalise abortion in the first trimester, keeping the procedure illegal except in limited cases like sexual assault or to protect the mother’s health; the stance comes as supporters push a new referendum and reports note around 40 women travel to Austria or Switzerland each year for abortions. Cancer Treatment Deal: IMPACT Therapeutics and Pharmanovia signed an exclusive licensing agreement worth up to €423.5m, expanding access to senaparib for maintenance therapy in advanced ovarian, fallopian tube, and primary peritoneal cancer across 66 countries, including Liechtenstein and other European markets. Healthcare Data Breach: Brown Health Medical Group-MA says a December 2025 incident exposed personal, medical, and financial data for 311,000 people, with the electronic health record system reported as unaffected. Cross-Border Health Context: UK guidance highlights how animal-product import rules can affect travelers returning from Liechtenstein and nearby countries—relevant for anyone planning trips that may intersect with health and wellness routines.

Abortion Access Clash: Liechtenstein’s regent, Hereditary Prince Alois, says he will veto any move to legalise abortion in the first trimester, keeping the country’s very limited exceptions (sexual assault or serious health risk) in place. Cancer Drug Deal: IMPACT Therapeutics and Pharmanovia signed an exclusive licensing agreement for senaparib, aiming to expand the ovarian cancer maintenance therapy across 66 countries, including Liechtenstein and the wider EEA. Public Health Research: New reporting highlights progress toward a “functional cure” for chronic hepatitis B, noting that millions in the EU/EEA (including Liechtenstein) live with the infection and often only learn after liver damage. Healthcare Data Breach: Brown Health Medical Group-MA says a breach affected 311,000 people, with personal, medical, and financial details potentially accessed. Food Import Rules: UK guidance warns travellers returning from Liechtenstein/Switzerland and other EU-linked countries not to bring back restricted meat and dairy items, with fines possible. Policy & Trade Pressure: Separate coverage notes renewed U.S. tariffs on Switzerland over forced-labour claims—relevant for regional health supply chains and compliance.